Stockscreener 앱 받기
1.10%
시간 외 거래:
전일 마감가:
$377.35
열려 있는:
$381.94
하루 거래량:
2.62M
Relative Volume:
0.98
시가총액:
$206.25B
수익:
$37.30B
순이익/손실:
$7.80B
주가수익비율:
26.53
EPS:
14.3793
순현금흐름:
$8.60B
1주 성능:
-12.75%
1개월 성능:
-8.12%
6개월 성능:
+4.18%
1년 성능:
+38.03%
1일 변동 폭
$376.76
$384.61
1주일 범위
$376.76
$410.02
52주 변동 폭
$269.77
$447.03
암젠 Stock (AMGN) Company Profile
명칭
Amgen Inc
전화
(805)447-1000
주소
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
381.50 | 204.01B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,138.28 | 994.49B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
266.32 | 640.02B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
261.77 | 454.36B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
144.85 | 355.10B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
138.99 | 260.70B | 54.66B | 13.58B | 16.05B | 7.0171 |
암젠 Stock (AMGN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-21 | 개시 | Canaccord Genuity | Hold |
| 2026-03-10 | 개시 | Jefferies | Hold |
| 2026-02-20 | 개시 | Barclays | Equal Weight |
| 2026-01-20 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 재개 | UBS | Buy |
| 2025-12-05 | 업그레이드 | Erste Group | Hold → Buy |
| 2025-11-24 | 재개 | Truist | Hold |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-09-03 | 재개 | Raymond James | Mkt Perform |
| 2025-05-20 | 재개 | Guggenheim | Neutral |
| 2025-04-22 | 재개 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Underperform |
| 2024-11-15 | 개시 | Wolfe Research | Peer Perform |
| 2024-11-14 | 개시 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Outperform |
| 2024-10-14 | 다운그레이드 | Truist | Buy → Hold |
| 2024-09-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-08-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2024-05-03 | 업그레이드 | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 재개 | Raymond James | Mkt Perform |
| 2024-02-07 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | 업그레이드 | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 개시 | Deutsche Bank | Hold |
| 2023-11-02 | 업그레이드 | Truist | Hold → Buy |
| 2023-10-20 | 재개 | JP Morgan | Neutral |
| 2023-10-17 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 재개 | BofA Securities | Neutral |
| 2023-09-06 | 개시 | HSBC Securities | Buy |
| 2023-04-24 | 재확인 | Oppenheimer | Outperform |
| 2023-03-13 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 재확인 | Truist | Buy |
| 2022-11-18 | 개시 | Credit Suisse | Underperform |
| 2022-10-31 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2022-10-11 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-02-09 | 재확인 | Barclays | Equal Weight |
| 2022-02-09 | 재확인 | Jefferies | Buy |
| 2022-02-09 | 재확인 | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 재확인 | Oppenheimer | Outperform |
| 2022-02-09 | 재확인 | Wells Fargo | Equal Weight |
| 2022-01-05 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-12-09 | 재개 | Wells Fargo | Equal Weight |
| 2021-12-06 | 개시 | Goldman | Buy |
| 2021-11-19 | 개시 | BMO Capital Markets | Market Perform |
| 2021-09-23 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 개시 | Daiwa Securities | Buy |
| 2020-10-28 | 개시 | UBS | Neutral |
| 2020-10-26 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | 업그레이드 | Truist | Hold → Buy |
| 2020-10-09 | 다운그레이드 | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | 다운그레이드 | Truist | Buy → Hold |
| 2020-10-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 재개 | Guggenheim | Neutral |
| 2020-03-31 | 개시 | Wolfe Research | Peer Perform |
| 2020-03-30 | 업그레이드 | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | 업그레이드 | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-01-31 | 다운그레이드 | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 개시 | Raymond James | Mkt Perform |
| 2019-12-17 | 재개 | Morgan Stanley | Overweight |
| 2019-11-12 | 개시 | SunTrust | Buy |
| 2019-11-05 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-08-19 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2019-05-23 | 업그레이드 | Citigroup | Neutral → Buy |
모두보기
암젠 주식(AMGN)의 최신 뉴스
Advancing Innovation in Small Cell Lung Cancer at WCLC 2026 – Amgen - Oncodaily
Amgen stock falls after HSBC downgrade and strong Q2 figures - ad-hoc-news.de
Is Amgen (AMGN) Fully Valued As New IMDELLTRA Data Reshapes The Story? - simplywall.st
Amgen stock falls after HSBC cuts its rating - ad-hoc-news.de
Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure - Yahoo Finance
Corient Private Wealth LP Decreases Position in Amgen Inc. $AMGN - MarketBeat
Does Amgen (AMGN) Change The Oncology Case With This Phase 3 Survival Win? - simplywall.st
Amgen Inc. stock underperforms Friday when compared to competitors - MarketWatch
Chip stocks lead Nasdaq's weekly gains; Amgen plunges after trial setback - TradingView
Amgen Highlights 26% Growth Drivers, IMDELLTRA Momentum and MariTide Potential - Yahoo Finance
Amgen Drops 10% on a Trial It Didn't Even Run - MarketBeat
Amgen vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Positive Lung Cancer Data Lifts the Case for Amgen and AstraZeneca - Yahoo Finance
Amgen vs. CRISPR Therapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Are Medical Stocks Lagging Amgen (AMGN) This Year? - Yahoo Finance
Amgen stock falls as HSBC downgrade and lower price target weigh on shares - ad-hoc-news.de
Amgen Inc. $AMGN Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance
Why Is the Market Watching Amgen (AMGN)? - Kalkine Media
Amgen stock heads into the open after a 2.25% drop - ad-hoc-news.de
Amgen (AMGN) Dips More Than Broader Market: What You Should Know - Yahoo Finance
Stock Traders Buy Large Volume of Put Options on Amgen (NASDAQ:AMGN) - MarketBeat
AMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study - The Globe and Mail
Amgen vs. Moderna: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Amgen’s New Repatha Plaque Trial: What Investors Should Watch - TipRanks
Amgen at Wells Fargo 21st Annual Healthcare Conference: growth broadens By Investing.com - Investing.com India
Amgen Inc at Wells Fargo Healthcare Conference Transcript - GuruFocus
Amgen stock dips as HSBC cuts rating and trims price target - ad-hoc-news.de
Amgen (AMGN) Stock Looks Cheap Relative To Fair Value - simplywall.st
HSBC Downgrades Amgen to Hold From Buy, Adjusts Price Target to $425 From $445 - marketscreener.com
Amgen Stock: Buy The Novartis-Driven Selloff (Rating Upgrade) (NASDAQ:AMGN) - Seeking Alpha
Sequoia Financial Advisors LLC Boosts Stock Holdings in Amgen Inc. $AMGN - MarketBeat
National Pension Service Has $465.74 Million Stake in Amgen Inc. $AMGN - MarketBeat
NewEdge Advisors LLC Has $33.69 Million Holdings in Amgen Inc. $AMGN - MarketBeat
AMGN - Finviz
HSBC lifts Novartis, downgrades Amgen in biopharma catalyst review By Investing.com - Investing.com South Africa
HSBC downgrades Amgen stock rating to Hold on valuation - investing.com
HSBC downgrades Amgen stock rating to Hold on valuation By Investing.com - Investing.com Canada
Amgen stock heads into the open after a 10.1 percent drop - ad-hoc-news.de
Amgen’s Forward Multiple Looks Cheap Until You Price The Margins It Assumes - Trefis
Could AstraZeneca (AZN)’s Stronger Growth Make it a Better Bet than Amgen (AMGN)? - Yahoo Finance
AMGEN TO PRESENT AT THE MORGAN STANLEY 24TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PR Newswire
Amgen's Imdelltra Sales Surge 115% as Lung-Cancer Combination Me - GuruFocus
Gordon Reid's Past Picks: Amgen, Qualcomm & United Rentals - BNN Bloomberg
Amgen’s Phase III DeLLphi-305 study deliverers strong results - thepharmaletter.com
Amgen's Imdelltra scores again in small cell lung cancer - pharmaphorum
Amgen stock falls sharply as trial read-through and Tavneos risk unsettle investors - ad-hoc-news.de
Amgen, AstraZeneca combination improves survival measures in late-stage lung cancer study - Yahoo Finance
Amgen and AstraZeneca report survival improvement in lung cancer trial - Yahoo Finance UK
Amgen Stock Sank 9.6% After Novartis’s Trial Failure and a Tavneos Suspension - TIKR.com
암젠 (AMGN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
암젠 주식 (AMGN) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
0.88%
자본화:
|
볼륨(24시간):